Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/213437
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Zugazagoitia, Jon | es_ES |
dc.contributor.author | Gómez-Rueda, Ana | es_ES |
dc.contributor.author | Jantus-Lewintre, Eloisa | es_ES |
dc.contributor.author | Isla, María Dolores | es_ES |
dc.contributor.author | Camps, Carlos | es_ES |
dc.contributor.author | Ramos, Inmaculada | es_ES |
dc.contributor.author | Trigo, José Manuel | es_ES |
dc.contributor.author | Bernabé Caro, Reyes | es_ES |
dc.contributor.author | Juan-Vidal, Óscar | es_ES |
dc.contributor.author | Sánchez-Torres, J. M. | es_ES |
dc.contributor.author | García-Campelo, R. | es_ES |
dc.contributor.author | Provencio, Mariano | es_ES |
dc.contributor.author | Felip, Enriqueta | es_ES |
dc.contributor.author | Castro, Javier de | es_ES |
dc.contributor.author | Faul, Iris | es_ES |
dc.contributor.author | Lanman, R. B. | es_ES |
dc.contributor.author | Ponce-Aix, Santiago | es_ES |
dc.contributor.author | Paz-Ares, Luis | es_ES |
dc.contributor.author | Garrido, Pilar | es_ES |
dc.date.accessioned | 2020-06-04T15:52:48Z | - |
dc.date.available | 2020-06-04T15:52:48Z | - |
dc.date.issued | 2019-08 | - |
dc.identifier.citation | Lung Cancer 134: 72-78 (2019) | es_ES |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | http://hdl.handle.net/10261/213437 | - |
dc.description.abstract | [Objectives] Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance. | es_ES |
dc.description.abstract | [Materials and methods] We conducted a multi-institutional prospective study including consecutive EGFR, ALK, or ROS1-altered NSCLC patients with TKI resistance from 12 Spanish institutions. Post-progression ctDNA NGS was performed by Guardant Health (Guardant360 assay). | es_ES |
dc.description.abstract | [Results] We included 53 patients separated in 3 cohorts: 31 EGFR-mutant NSCLCs with first/second-generation TKI resistance (cohort 1), 15 EGFR T790M + NSCLCs with osimertinib resistance (cohort 2), and 7 ALK/ROS1-rearranged NSCLCs with crizotinib and/or next-generation TKI resistance (cohort 3). Besides Guardant360, 22 patients from cohort 1 (71%) underwent post-progression tumor biopsies and/or alternative plasma-based genotyping. In the entire study population, 34 patients (64%) had reliable evidence of tumor-DNA shed for resistance assessment, and 24 patients (45%) had actionable alterations. Target-independent pathogenic alterations were frequently detected, particularly at osimertinib resistance. Eleven patients (20%) received subsequent molecular-guided therapies indicated by plasma NGS alone (n = 9, 17%), or plasma NGS and tissue sequencing (n = 2, 4%), deriving the expected clinical benefit. Of these, 9 had EGFR T790 M mutation and received osimertinib, 1 had ALK G1202R mutation and received lorlatinib, and 1 had ROS1 G2032R mutation and received cabozantinib. Two additional cases from cohort 1 (6%) had undetectable EGFR T790 M by Guardant360 but were T790M + by tissue and BEAMing digital PCR respectively, and also received osimertinib. | es_ES |
dc.description.abstract | [Conclusion] NGS of ctDNA detects actionable alterations in a large proportion of oncogene-driven NSCLC patients with TKI resistance, and can be used to guide subsequent treatments as a complement or alternative to tissue or PCR-based plasma genotyping in the real-world clinical setting. | es_ES |
dc.description.sponsorship | J. Zugazagoitia was funded by Instituto de Salud Carlos III (Rio Hortega, CM15/00196). E. Jantus-Lewintre and C. Camps were funded by CIBERONC (CB16/12/00350). P Garrido was funded by ISCIII: PIE15/00050, and CIBERONC (C16/12/00442). L. Paz-Ares was funded by ISCIII: PI1401964, PIE15/00076, RTICC (R12/0036/0028), CIBERONC (C16/12/00442), and CAM (B2017/BMP-3884), co-funded by FEDER from Regional Development European Funds (European Union). M: Provencio was funded by ISCIII: PIE 1400/64, PI16/01818 and European Union Funds: H2020-sc1-2016-2017. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | closedAccess | es_ES |
dc.subject | Oncogene-driven NSCLC | es_ES |
dc.subject | TKI resistance | es_ES |
dc.subject | Osimertinib | es_ES |
dc.subject | ctDNA | es_ES |
dc.subject | Digital next-generation sequencing | es_ES |
dc.title | Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1016/j.lungcan.2019.05.032 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.lungcan.2019.05.032 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red Cáncer (España) | es_ES |
dc.contributor.funder | Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares (España) | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Comunidad de Madrid | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/100012818 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
23
checked on 04-mar-2024
WEB OF SCIENCETM
Citations
21
checked on 27-feb-2024
Page view(s)
131
checked on 19-abr-2024
Download(s)
27
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.